QGEN Stock — Price, Charts & Analysis

Qiagen N.V. (QGEN) has a trailing P/E of 22.68x and a forward P/E of 17.21x. This places QGEN in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

QGEN trades with 22.68x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether QGEN looks overvalued or undervalued.

QGEN's P/E of 22.68x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

QGEN's trailing EPS is $1.98 and forward EPS is $2.61. Reported earnings growth is 13.60%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Qiagen N.V. generated for each share. QGEN's trailing EPS is $1.98, and investors usually prefer EPS that is positive and growing over time.

Qiagen N.V. has a market cap of $9.27B, making QGEN a mid-cap stock based on the current market value shown on Worldtickers.

QGEN's latest stock price on Worldtickers is $44.90. The latest move is $0.40 or 0.90%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

QGEN's quote includes a latest price of $44.90. The market open is $44.21. Previous close is $44.50. The intraday range is $44.21 to $45.53.

QGEN is up in the latest quote, with a move of $0.40 or 0.90%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

QGEN generated $2.10B in trailing revenue. Revenue growth is 0.30%, which helps show whether demand is expanding or slowing.

QGEN's revenue growth is 0.30%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, QGEN shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $409.32M.

Gross margin is 66.39%. Margins show how efficiently Qiagen N.V. turns revenue into profit.

Qiagen N.V. carries $1.65B and holds $793.50M in cash.

QGEN holds $793.50M on its balance sheet.

QGEN's book value per share is $16.26.

Yes, Qiagen N.V. pays a dividend of $0.35 per share annually. The dividend yield is 79.00%. The payout ratio is 17.79%.

QGEN's dividend yield is 79.00%. Its payout ratio is 17.79%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for QGEN. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Qiagen N.V.'s investor relations materials.

Institutions hold 80.21% of QGEN shares. Insiders hold 0.48% of shares. Ownership mix helps investors understand how much of Qiagen N.V. is held by professional investors and company insiders.

QGEN has 206.5M shares outstanding. Float shares are 205.12M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for QGEN, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for QGEN is $2.61. Earnings growth is 13.60%. Revenue growth is 0.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

QGEN's trailing EPS is $1.98. Forward EPS is $2.61. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

QGEN is in the Healthcare sector. Its earnings multiple is 22.68x. Its latest displayed growth metric is 0.30%. Compare these figures with sector peers before deciding whether Qiagen N.V. is stronger or weaker than average.

QGEN trades at $44.90. The stock trades at 22.68x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Qiagen N.V.'s fundamentals.

QGEN risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.62, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

QGEN should be compared with companies in Diagnostics & Research. Its earnings multiple is 22.68x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Qiagen N.V. (QGEN) operates in Healthcare, specifically Diagnostics & Research. Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and inst

QGEN trades on NYSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

QGEN stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Qiagen N.V.'s official website listed on Worldtickers is www.qiagen.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Qiagen N.V. employs about 5.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Qiagen N.V. is headquartered in Venlo, Netherlands. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

QGEN is in the Healthcare sector and the Diagnostics & Research industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

QGEN has traded between $32.53 and $57.82 over the past 52 weeks. At $44.90, it is 22.35% below the high and 38.03% above the low. The 52-week range helps gauge long-term price momentum.

QGEN is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $40.43 and its 200-day moving average is $42.45.

QGEN's RSI is 67.62. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

QGEN's latest RSI reading is 67.62, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for QGEN is near $40.51. Key resistance is near $44.82. Breaks above resistance or below support can change the short-term technical setup.

QGEN's nearest reported support level is $40.51. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

QGEN's nearest reported resistance level is $44.82. A breakout above resistance can improve momentum, especially when volume confirms the move.

QGEN trades about 2.81M shares daily on average. The latest displayed volume is 4.8M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

QGEN's MACD is 0.08, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

QGEN is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 67.62 (neutral). MACD is bullish. Nearest support is around $40.51. Resistance is around $44.82. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $42.50 (5.64% from price). MA50 is $40.43 (11.06% from price). MA200 is $42.45 (5.77% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. QGEN's MA20 is $42.50. MA50 is $40.43. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

QGEN's pivot is near $44.24. Support is near $40.51. Resistance is near $44.82. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for QGEN is near $42.66. The next upper resistance zone is near $51.73. These levels help define risk and possible follow-through zones after a breakout or breakdown.

QGEN's Bollinger range is roughly $40.51 to $44.49. Band width is near 9.35%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

QGEN's ATR-based typical daily range is about 2.60%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 4.8M shares. Average volume is about 2.81M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

QGEN's all-time high shown on Worldtickers is $62.76. Its all-time low is $1.88. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

QGEN has a beta of 0.62, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.